Researching healthcare and technology companies of interest to Mighty Capital, a Silicon Valley venture firm focused on products that transform lives and create value at scale.

CEO and co-founder of Serenium, a healthcare IT company, developing a scalable internet-of-things sleep apnea diagnostic system for consumers and patients. The system utilizes a machine learning AI cloud-based algorithm, an App and a standard one-channel medical device to deliver sleep apnea risk metrics that are clinically comparable to in-patient sleep lab systems (PSG) for children and adults. • Formed Delaware company;• Raised Seed capital (convertible debt);• Pivoted from an initial product concept to a new diagnostic solution;• Secured IP and Trade Secret contracts for product development (USA & EU)t;• Completed and managed clinical trials for the algorithm (n=4,191) and the prototype testing product (n=432); • Managed and negotiated with an overseas supplier; • Hired and managed a software development team; • Partnered with a Chinese / Hong Kong hospital group for local distribution; • Acting-CFO, managing all financial activities;• Managing legal, administrative and related issues.

Designed and taught an introductory finance evening course, Fundamentals of Investments (Business 061), to at local community college in the San Francisco Bay Area.

Partner with start-up Founders and leadership to develop commercial partnerships and alliances for biotech, pharmaceuticals, medical delivery, nutritionals, medical devices and others to achieve business objectives. 2013 - 2014• Serenium: partnering, alliance negotiations and business management for wellness business• Trendicy: provide commercial development & partnering services for Big Data firm• Undisclosed Healthcare: contribute business development support and planning for new technologies • IMPACTMeds: supplied business development, financial & management for a health IT start-up 2010-2013• GRDG / ATM Metabolics: provided business development negotiations for products (glucose control, Alzheimer) • Undisclosed Biotech: contributed strategic commercialization planning and branding alternatives• Nova Nano Diagnostics: developed a new diagnostics company creating ultrasensitive tools for biomarkers • ComChart: led partnering/acquisition discussions for an EMR company• Undisclosed Biotech: provided strategic consultation for an immunological company with Astia2008-2011• 5MinFun.com: founded an online educational vocabulary game

Led a private biotechnology company developing a new transdermal drug delivery system. The inherited business plan anticipated industry partnering to fund development, but that plan did not fully appreciate scale-up issues. Managed the business including R&D, Clinical Development, Regulatory, Marketing, Engineering, Finance and HR. Completed a key Phase 2 development study, business development partnership negotiations, the relocation to new facilities and the management of general business activities.

Served on the Board of Directors for Critical Therapeutics, (CRTX) a publicly traded company, assisted in a strategic repositioning, which was resolved by a reverse merger (May 2008).

Purchased from DuPont Pharmaceutical Company in 2001. Restructured company and integrated it into BMS. Directed development of business plan, changed distribution model, and supervised performance for global pharmaceutical imaging business. Achievements: • Increased annual sales of original product line from $ 400M per year to $ 600M.• Doubled annual profit to over $ 200M. • Negotiated and managed key distribution alliances and business development partners.• Accelerated product development (7 new programs) under new R&D Operating Committee structure. • Developed proactive global business culture.

Headed the global commercial marketing and clinical development team for a diabetes product in Phase 2 development. Developed global strategies and product positioning, formulated and implemented clinical and regulatory programs.• Integrated the acquired Medical Imaging Company (from the DuPont Pharmaceutical Co.) into BMS prior to being appointed its President, while simultaneously managing this role.

Managed 500 people selling antibiotics, neurological and dermatological products with sales over $ 600 million. Launched Tequin (quinolone antibiotic), rated by IMS (Intercontinental Marketing Services) as the most successful launch in 2000.

Managed Thai pharmaceutical and consumer medicines business, with P&L accountability, and marketing, sales and regulatory teams.• Improved competitive pharmaceutical industry ranking from 8th to 3rd place in two years during Asian economic crisis and generated momentum to achieve 1st place one year post tenure • Negotiated long term supply agreement with government agencies• Elected Vice President of Thai industry association

Negotiated partnerships and contracts, managed alliances, developed creative strategies, analyzed financial returns and led national accounts team for large Managed Health Care customers • Implemented innovative multi-million dollar partnerships to drive product profits

Various marketing and financial roles at BMS.

Directed and successfully launched a new anti-hypertension drug (Monopril) in Melbourne, Australia.

General management consulting.

Asset and currency trading.

General personal financial planning.